Publications by authors named "M O Barbaza"

Article Synopsis
  • * A total of 280 patients were included, with 71% undergoing molecular biology tests at diagnosis, revealing diverse tumor types and a significant overall survival rate of 85% over a median follow-up of 40 months.
  • * The results indicated that broad-spectrum genomic analyses were more successful in identifying actionable variants for targeted therapies compared to targeted tests alone, with 23% of patients receiving matched therapies after their first relapse.
View Article and Find Full Text PDF

Background: Since meals are a special moment in the parent-infant relationship and functional gastrointestinal disorders (FGD) are frequent in infants, this study mainly aimed to describe the frequency of exposure to screens during meals in infants with FGD.

Methods: This French non-interventional, cross-sectional, and multicenter study was conducted with FGD infants (aged 1-12 months), consecutively included by private pediatricians and general practitioners. Descriptive analysis was performed.

View Article and Find Full Text PDF

Background: The aim of this study was to estimate the frequency of functional gastrointestinal disorders (FGIDs) in infants aged up to 12 months according to the new ROME IV criteria defining these disorders, and to describe the management of FGIDs in France.

Methods: This French non-interventional, cross-sectional, and multicenter study was conducted among private-outpatient physicians who each included four consecutive patients aged up to 12 months. The frequency of FGIDs was described using the ROME IV criteria versus clinicians' diagnosis.

View Article and Find Full Text PDF

The use of foodstuff as natural medicines has already been established through studies demonstrating the pharmacological activities that they exhibit. Knowing the nutritional and pharmacological significance of foods enables the understanding of their role against several diseases. Among the foods that can potentially be considered as medicine, is sesame or L.

View Article and Find Full Text PDF

The poor outcome of patients with recurrent ovarian cancer constitutes a continuous challenge for decision-making in clinical practice. In this setting, molecular targets have recently been identified, and novel compounds are now available. Bevacizumab has been introduced for the treatment of patients with ovarian cancer and is, to date, the most extensively investigated targeted therapy in this setting.

View Article and Find Full Text PDF